Completed PHASE2 INTERVENTIONAL 1-arm NCT03443128

Vinorelbine for Recurrent ALCL-2017

Phase II Study of Vinorelbine for Children with Recurrent Anaplastic Large Cell Lymphoma

Sponsor: Children's Cancer Group, China

Conditions Anaplastic Large Cell Lymphoma Vinorelbine

Interventions Vinorelbine

Updated 10 times since 2018 Last updated: Feb 11, 2025 Started: Nov 30, 2016 Primary completion: Dec 31, 2024 Completion: Feb 28, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Anaplastic Large Cell Lymphoma and Vinorelbine, this trial is completed. The trial is conducted by Children's Cancer Group, China and has accumulated 10 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

10 versions recorded

Mar 2025 — Present [monthly]

Completed PHASE2

Status: Recruiting → Completed
Sep 2024 — Mar 2025 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Sep 2022 — Jul 2024 [monthly]

Recruiting PHASE2
Sep 2021 — Sep 2022 [monthly]

Recruiting PHASE2

▶ Show 5 earlier versions

Jan 2021 — Sep 2021 [monthly]

Recruiting PHASE2
Aug 2020 — Jan 2021 [monthly]

Recruiting PHASE2
Mar 2019 — Aug 2020 [monthly]

Recruiting PHASE2
Jun 2018 — Mar 2019 [monthly]

Recruiting PHASE2
Mar 2018 — Jun 2018 [monthly]

Recruiting PHASE2

First recorded

Nov 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Children's Cancer Group, China

Data source: Children's Cancer Group, China

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China